

World Journal of *Clinical Cases*

World J Clin Cases 2022 November 16; 10(32): 11665-12065



Contents

Thrice Monthly Volume 10 Number 32 November 16, 2022

OPINION REVIEW

- 11665** Combined use of lactoferrin and vitamin D as a preventive and therapeutic supplement for SARS-CoV-2 infection: Current evidence

Cipriano M, Ruberti E, Tovani-Palone MR

REVIEW

- 11671** Role of adherent invasive *Escherichia coli* in pathogenesis of inflammatory bowel disease
- Zheng L, Duan SL, Dai YC, Wu SC*
- 11690** Emerging potential of ubiquitin-specific proteases and ubiquitin-specific proteases inhibitors in breast cancer treatment

Huang ML, Shen GT, Li NL

MINIREVIEWS

- 11702** Overlap of diabetic ketoacidosis and hyperosmolar hyperglycemic state
- Hassan EM, Mushtaq H, Mahmoud EE, Chhibber S, Saleem S, Issa A, Nitesh J, Jama AB, Khedr A, Boike S, Mir M, Attallah N, Surani S, Khan SA*

ORIGINAL ARTICLE

Case Control Study

- 11712** Comparing the efficacy of different dexamethasone regimens for maintenance treatment of multiple myeloma in standard-risk patients non-eligible for transplantation

Hu SL, Liu M, Zhang JY

Retrospective Cohort Study

- 11726** Development and validation of novel nomograms to predict survival of patients with tongue squamous cell carcinoma

Luo XY, Zhang YM, Zhu RQ, Yang SS, Zhou LF, Zhu HY

Retrospective Study

- 11743** Non-invasive model for predicting esophageal varices based on liver and spleen volume

Yang LB, Zhao G, Tantai XX, Xiao CL, Qin SW, Dong L, Chang DY, Jia Y, Li H

Clinical Trials Study

- 11753** Clinical efficacy of electromagnetic field therapy combined with traditional Chinese pain-reducing paste in myofascial pain syndrome

Xiao J, Cao BY, Xie Z, Ji YX, Zhao XL, Yang HJ, Zhuang W, Sun HH, Liang WM

- 11766** Endothelial injury and inflammation in patients with hyperuricemic nephropathy at chronic kidney disease stages 1-2 and 3-4

Xu L, Lu LL, Wang YT, Zhou JB, Wang CX, Xin JD, Gao JD

Observational Study

- 11775** Quality of life and symptom distress after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy

Wang YF, Wang TY, Liao TT, Lin MH, Huang TH, Hsieh MC, Chen VCH, Lee LW, Huang WS, Chen CY

- 11789** Development and validation of a risk assessment model for prediabetes in China national diabetes survey

Yu LP, Dong F, Li YZ, Yang WY, Wu SN, Shan ZY, Teng WP, Zhang B

Case Control Study

- 11804** T-cell immunoglobulin mucin molecule-3, transformation growth factor β , and chemokine-12 and the prognostic status of diffuse large B-cell lymphoma

Wu H, Sun HC, Ouyang GF

META-ANALYSIS

- 11812** Prostate artery embolization on lower urinary tract symptoms related to benign prostatic hyperplasia: A systematic review and meta-analysis

Wang XY, Chai YM, Huang WH, Zhang Y

CASE REPORT

- 11827** Paraneoplastic neurological syndrome caused by cystitis glandularis: A case report and literature review

Zhao DH, Li QJ

- 11835** Neck pain and absence of cranial nerve symptom are clues of cervical myelopathy mimicking stroke: Two case reports

Zhou LL, Zhu SG, Fang Y, Huang SS, Huang JF, Hu ZD, Chen JY, Zhang X, Wang JY

- 11845** Nine-year survival of a 60-year-old woman with locally advanced pancreatic cancer under repeated open approach radiofrequency ablation: A case report

Zhang JY, Ding JM, Zhou Y, Jing X

- 11853** Laparoscopic treatment of inflammatory myofibroblastic tumor in liver: A case report

Li YY, Zang JF, Zhang C

- 11861** Survival of a patient who received extracorporeal membrane oxygenation due to postoperative myocardial infarction: A case report

Wang QQ, Jiang Y, Zhu JG, Zhang LW, Tong HJ, Shen P

- 11869** Triple hit to the kidney-dual pathological crescentic glomerulonephritis and diffuse proliferative immune complex-mediated glomerulonephritis: A case report

Ibrahim D, Brodsky SV, Satoskar AA, Biederman L, Maroz N

- 11877** Successful transcatheter arterial embolization treatment for chest wall haematoma following permanent pacemaker implantation: A case report
Zheng J, Tu XM, Gao ZY
- 11882** Brachiocephalic to left brachial vein thrombotic vasculitis accompanying mediastinal pancreatic fistula: A case report
Kokubo R, Yunaiyama D, Tajima Y, Kugai N, Okubo M, Saito K, Tsuchiya T, Itoi T
- 11889** Long survival after immunotherapy plus paclitaxel in advanced intrahepatic cholangiocarcinoma: A case report and review of literature
He MY, Yan FF, Cen KL, Shen P
- 11898** Successful treatment of pulmonary hypertension in a neonate with bronchopulmonary dysplasia: A case report and literature review
Li J, Zhao J, Yang XY, Shi J, Liu HT
- 11908** Idiopathic tenosynovitis of the wrist with multiple rice bodies: A case report and review of literature
Tian Y, Zhou HB, Yi K, Wang KJ
- 11921** Endoscopic resection of bronchial mucoepidermoid carcinoma in a young adult man: A case report and review of literature
Ding YM, Wang Q
- 11929** Blue rubber bleb nevus syndrome complicated with disseminated intravascular coagulation and intestinal obstruction: A case report
Zhai JH, Li SX, Jin G, Zhang YY, Zhong WL, Chai YF, Wang BM
- 11936** Management of symptomatic cervical facet cyst with cervical interlaminar epidural block: A case report
Hwang SM, Lee MK, Kim S
- 11942** Primary squamous cell carcinoma with sarcomatoid differentiation of the kidney associated with ureteral stone obstruction: A case report
Liu XH, Zou QM, Cao JD, Wang ZC
- 11949** Successful live birth following hysteroscopic adhesiolysis under laparoscopic observation for Asherman's syndrome: A case report
Kakinuma T, Kakinuma K, Matsuda Y, Ohwada M, Yanagida K
- 11955** What is responsible for acute myocardial infarction in combination with aplastic anemia? A case report and literature review
Zhao YN, Chen WW, Yan XY, Liu K, Liu GH, Yang P
- 11967** Repeated ventricular bigeminy by trigeminocardiac reflex despite atropine administration during superficial upper lip surgery: A case report
Cho SY, Jang BH, Jeon HJ, Kim DJ
- 11974** Testis and epididymis-unusual sites of metastatic gastric cancer: A case report and review of the literature
Ji JJ, Guan FJ, Yao Y, Sun LJ, Zhang GM

- 11980** t(4;11) translocation in hyperdiploid *de novo* adult acute myeloid leukemia: A case report
Zhang MY, Zhao Y, Zhang JH
- 11987** Sun-burn induced upper limb lymphedema 11 years following breast cancer surgery: A case report
Li M, Guo J, Zhao R, Gao JN, Li M, Wang LY
- 11993** Minimal change disease caused by polycythemia vera: A case report
Xu L, Lu LL, Gao JD
- 12000** Vitreous amyloidosis caused by a Lys55Asn variant in transthyretin: A case report
Tan Y, Tao Y, Sheng YJ, Zhang CM
- 12007** Endoscopic nasal surgery for mucocoele and pyogenic mucocoele of turbinate: Three case reports
Sun SJ, Chen AP, Wan YZ, Ji HZ
- 12015** Transcatheter arterial embolization for traumatic injury to the pharyngeal branch of the ascending pharyngeal artery: Two case reports
Yunaiyama D, Takara Y, Kobayashi T, Muraki M, Tanaka T, Okubo M, Saguchi T, Nakai M, Saito K, Tsukahara K, Ishii Y, Homma H
- 12022** Retroperitoneal leiomyoma located in the broad ligament: A case report
Zhang XS, Lin SZ, Liu YJ, Zhou L, Chen QD, Wang WQ, Li JY
- 12028** Primary testicular neuroendocrine tumor with liver lymph node metastasis: A case report and review of the literature
Xiao T, Luo LH, Guo LF, Wang LQ, Feng L
- 12036** Endodontic treatment of the maxillary first molar with palatal canal variations: A case report and review of literature
Chen K, Ran X, Wang Y
- 12045** Langerhans cell histiocytosis involving only the thymus in an adult: A case report
Li YF, Han SH, Qie P, Yin QF, Wang HE

LETTER TO THE EDITOR

- 12052** Heart failure with preserved ejection fraction: A distinct heart failure phenotype?
Triposkiadis F, Giamouzis G, Skoularigis J, Xanthopoulos A
- 12056** Insight into appropriate medication prescribing for elderly in the COVID-19 era
Omar AS, Kaddoura R
- 12059** Commentary on "Gallstone associated celiac trunk thromboembolisms complicated with splenic infarction: A case report"
Tokur O, Aydın S, Kantarci M
- 12062** Omicron targets upper airways in pediatrics, elderly and unvaccinated population
Nori W, Ghani Zghair MA

ABOUT COVER

Editorial Board Member of *World Journal of Clinical Cases*, Camelia Cristina Diaconu, FACC, FACP, FESC, MHSc, PhD, Associate Professor, Department of Internal Medicine, "Carol Davila" University of Medicine and Pharmacy, Clinical Emergency Hospital of Bucharest, Bucharest 014461, Romania. drcameliadiaconu@gmail.com

AIMS AND SCOPE

The primary aim of *World Journal of Clinical Cases* (WJCC, *World J Clin Cases*) is to provide scholars and readers from various fields of clinical medicine with a platform to publish high-quality clinical research articles and communicate their research findings online.

WJCC mainly publishes articles reporting research results and findings obtained in the field of clinical medicine and covering a wide range of topics, including case control studies, retrospective cohort studies, retrospective studies, clinical trials studies, observational studies, prospective studies, randomized controlled trials, randomized clinical trials, systematic reviews, meta-analysis, and case reports.

INDEXING/ABSTRACTING

The WJCC is now abstracted and indexed in Science Citation Index Expanded (SCIE, also known as SciSearch®), Journal Citation Reports/Science Edition, Current Contents®/Clinical Medicine, PubMed, PubMed Central, Scopus, Reference Citation Analysis, China National Knowledge Infrastructure, China Science and Technology Journal Database, and Superstar Journals Database. The 2022 Edition of Journal Citation Reports® cites the 2021 impact factor (IF) for WJCC as 1.534; IF without journal self cites: 1.491; 5-year IF: 1.599; Journal Citation Indicator: 0.28; Ranking: 135 among 172 journals in medicine, general and internal; and Quartile category: Q4. The WJCC's CiteScore for 2021 is 1.2 and Scopus CiteScore rank 2021: General Medicine is 443/826.

RESPONSIBLE EDITORS FOR THIS ISSUE

Production Editor: Hua-Ge Yin; Production Department Director: Xu Guo; Editorial Office Director: Jin-Lei Wang.

NAME OF JOURNAL

World Journal of Clinical Cases

ISSN

ISSN 2307-8960 (online)

LAUNCH DATE

April 16, 2013

FREQUENCY

Thrice Monthly

EDITORS-IN-CHIEF

Bao-Gan Peng, Jerzy Tadeusz Chudek, George Kontogeorgos, Maurizio Serati, Ja Hyeon Ku

EDITORIAL BOARD MEMBERS

<https://www.wjgnet.com/2307-8960/editorialboard.htm>

PUBLICATION DATE

November 16, 2022

COPYRIGHT

© 2022 Baishideng Publishing Group Inc

INSTRUCTIONS TO AUTHORS

<https://www.wjgnet.com/bpg/gerinfo/204>

GUIDELINES FOR ETHICS DOCUMENTS

<https://www.wjgnet.com/bpg/GerInfo/287>

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH

<https://www.wjgnet.com/bpg/gerinfo/240>

PUBLICATION ETHICS

<https://www.wjgnet.com/bpg/GerInfo/288>

PUBLICATION MISCONDUCT

<https://www.wjgnet.com/bpg/gerinfo/208>

ARTICLE PROCESSING CHARGE

<https://www.wjgnet.com/bpg/gerinfo/242>

STEPS FOR SUBMITTING MANUSCRIPTS

<https://www.wjgnet.com/bpg/GerInfo/239>

ONLINE SUBMISSION

<https://www.f6publishing.com>



Retrospective Study

Non-invasive model for predicting esophageal varices based on liver and spleen volume

Long-Bao Yang, Gang Zhao, Xin-Xing Tantai, Cai-Lan Xiao, Si-Wen Qin, Lei Dong, Dan-Yan Chang, Yuan Jia, Hong Li

Specialty type: Gastroenterology and hepatology

Provenance and peer review:

Unsolicited article; Externally peer reviewed.

Peer-review model: Single blind

Peer-review report's scientific quality classification

Grade A (Excellent): 0
Grade B (Very good): 0
Grade C (Good): C, C
Grade D (Fair): 0
Grade E (Poor): 0

P-Reviewer: Kumar R, India; Shen L, China

Received: August 28, 2022

Peer-review started: August 28, 2022

First decision: October 4, 2022

Revised: October 7, 2022

Accepted: October 18, 2022

Article in press: October 18, 2022

Published online: November 16, 2022



Long-Bao Yang, Gang Zhao, Xin-Xing Tantai, Cai-Lan Xiao, Lei Dong, Dan-Yan Chang, Yuan Jia, Hong Li, Department of Gastroenterology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, Shaanxi Province, China

Si-Wen Qin, Department of Medicine, Xi'an Jiaotong University, Xi'an 710004, Shaanxi Province, China

Corresponding author: Hong Li, MD, Doctor, Department of Gastroenterology, The Second Affiliated Hospital of Xi'an Jiaotong University, No. 157 Xiwu Road, Xi'an 710004, Shaanxi Province, China. hongli119@hotmail.com

Abstract

BACKGROUND

Upper endoscopy is the gold standard for predicting esophageal varices in China. Guidelines and consensus suggest that patients with liver cirrhosis should undergo periodic upper endoscopy, most patients undergo their first upper endoscopy when esophageal variceal bleeds. Therefore, it is important to develop a non-invasive model to early diagnose esophageal varices.

AIM

To develop a non-invasive predictive model for esophageal varices based on liver and spleen volume in viral cirrhosis patients.

METHODS

We conducted a cross-sectional study based on viral cirrhosis crowd in the Second Affiliated Hospital of Xi'an Jiaotong University. By collecting the basic information and clinical data of the participants, we derived the independent risk factors and established the prediction model of esophageal varices. The established model was compared with other models. Area under the receiver operating characteristic curve, calibration plot and decision curve analysis were used to test the discriminating ability, calibration ability and clinical practicability in both the internal and external validation.

RESULTS

The portal vein diameter, the liver and spleen volume, and volume change rate were the independent risk factors of esophageal varices. We successfully used the factors to establish the predictive model [area under the curve (AUC) 0.87, 95%CI:

0.80-0.95], which showed better predictive value than other models. The model showed good discriminating ability, calibration ability and the clinical practicability in both modelling group and external validation group.

CONCLUSION

The developed non-invasive predictive model can be used as an effective tool for predicting esophageal varices in viral cirrhosis patients.

Key Words: Gastroscopy; Esophageal varices; Liver volume; Cirrhosis; Non-invasive diagnostic model; Spleen volume

©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: An effective novel non-invasive predictive model based on the standard liver and spleen volume formula for esophageal varices in individuals with viral cirrhosis was developed. The model's specificity, calibrability, and clinical efficacy were superior to other models.

Citation: Yang LB, Zhao G, Tantai XX, Xiao CL, Qin SW, Dong L, Chang DY, Jia Y, Li H. Non-invasive model for predicting esophageal varices based on liver and spleen volume. *World J Clin Cases* 2022; 10(32): 11743-11752

URL: <https://www.wjgnet.com/2307-8960/full/v10/i32/11743.htm>

DOI: <https://dx.doi.org/10.12998/wjcc.v10.i32.11743>

INTRODUCTION

Esophageal varices (EVs) frequently occur in patients with cirrhosis. Presently, upper endoscopy is the most effective approach and gold standard for predicting EVs[1]. For patients with cirrhosis, guidelines and consensus statements strongly recommend periodic upper endoscopy[2]. In China, upper endoscopy is usually not performed under sedation, thus, the procedure may result in discomfort and psychological burden on patients. As a result, some patients do not accept upper endoscopy until EVs bleed.

In individuals with cirrhosis and liver transplantation, the measurement of the liver volume and spleen volume is essential[3,4]. Despite the usage of computed tomography (CT) and magnetic resonance imaging could be used for estimating the liver and spleen volume, these techniques were tedious. In our previous study, we used 207 healthy Chinese patient's body surface area (BSA) data, established the standard liver volume (SLV) and standard spleen volume formulas (SSV), as follow: $SLV = 858.186 \times BSA - 393.349$ ($R^2 = 0.350$), $SSV = 188.813 \times BSA - 140.981$ ($R^2 = 0.126$)[5]. Based on the derived formulas, a non-invasive predictive model for high-risk EVs in viral cirrhosis patients was developed[5].

Until now, several models were established to predict EVs. The APRI (aspartate aminotransferase platelet ratio index)[6], the AAR (aspartate aminotransferase: Alanine aminotransferase ratio)[6], LSPS (liver stiffness/Spleen diameter Platelet Score)[7] and VRI (variceal risk index)[8] are the more traditional non-invasive prediction models used to predict EVs. Liver stiffness measure (LSM), spleen diameter, platelet, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) were put in the models. The use of SLV and SSV calculation formulas to construct a non-invasive prediction model for EVs in patients with liver cirrhosis has not been reported. Bavono VI recommended that liver stiffness and platelets be used to predict EVs[9]. In China, most hospitals could not offer FibroScan or FibroTouch to detect LSM. For the preliminary prediction of EVs, the study was aimed to develop a non-invasive predictive model for EVs based on liver and spleen volume in viral cirrhosis patients.

MATERIALS AND METHODS

Subject

We conducted a cross-sectional study in the Second Affiliated Hospital of Xi'an Jiaotong University from October 2017 to December 2018, each participant in our study was diagnosed as viral cirrhosis and underwent upper endoscopy and CT. The diagnosis of liver cirrhosis is based on symptoms, signs, biochemical tests and more than 2 kinds of imaging findings. Inclusion criteria: Hepatitis B or C viral cirrhosis positive; upper abdominal CT, biochemical, as well as upper endoscopy examinations; over 18 years old. Exclusion criteria: With other types of cirrhosis; suspected liver tumor; benign disorders

which alter spleen and liver volume; patients having medium/Large ascites; history of spleen or liver resection; other conditions that can potentially affect the portal vein/splenic vein hemodynamic; unreliable LSM; other conditions that may have an effect on LSM, like BMI > 35 kg/m²; severe weight loss or malnutrition; history of esophageal varices bleeding and endoscopic/surgical treatment; hematological diseases altering spleen volume. Based on the upper endoscopy result, subjects were defined as EVs group, others were defined as non-EVs group. A total of 111 subjected was enrolled as the modeling group, including 86 subjects with EVs and 25 subjects without EVs. Our study was approved by the Ethics Committee of Xi'an Jiaotong University, Shaanxi, China (NO. 2017-445). Informed consent was waived by the Ethics Committee of Xi'an Jiaotong University as patients were identified retrospectively, according to institutional review board exempt protocols.

Basic information and clinical data

We collected sex, age, body weight (BW), body height (BH), etiology, course of cirrhosis, and Child-Pugh score of the subjects. The Mosteller's formula was used to compute the patient's BSA [$BSA = \sqrt{[BW \text{ (kg)} \times BH \text{ (cm)}]/3600}$]. The Child-Pugh scoring method was used to grade cirrhosis patient's scores. Blood test results [aspartate aminotransferase (AST), alanine aminotransferase (ALT), total bilirubin (TBil), direct bilirubin (DBil) and platelets (PLT)] were also collected.

Determination of liver and spleen volume

The actual liver volume and spleen volume were calculated by the multi-slice spiral CT scanner (GE 128-slice spiral CT scanner; Linux Medical System, United States) with a 5 mm reconstructed layer thickness and five seconds-time interval, and were defined as CTLV and CTSV, respectively. The SLV and SSV were calculated by our previously derived formulas [$SSV = 188.813 \times BSA - 140.981$ ($R^2 = 0.126$), and $SLV = 858.186 \times BSA - 393.349$ ($R^2 = 0.350$)]. The volume change was equal to the different value between the volume calculated by formulas and CT. The volume change rate was equal to the volume change divide by the volume calculated by formulas. PVSA (portal vein surface area), PVD (portal vein diameter), and SVD (spleen vein diameter) were also recorded.

LSM by transient elastography and Upper endoscopy

LSM was performed using FibroScan (Echosens, France) and FibroTouch (Haishkell Medical Technology Centre, China) equipment[10,11]. The TE results were obtained retrospectively and presented in kilopascals (kPa). We selected the lower interquartile/lower median variability values for patients having more LSM. Blood routine assessment, hepatitis detection, liver and renal function examination were done in all patients, using suitable equipment. Experienced doctors examined EVs by the help of an electronic upper endoscopy (Olympus, Tokyo, Japan) and then assigned them into two groups: EVs group and non-EVs group.

Model development

All data analysis were carried out using IBM SPSS Statistics 26.0 (SPSS, Inc., Chicago, IL, United States). It was considered statistically significant when $P < 0.05$ (two side test). We set EVs diagnosis as dependent variable, data collected as independent variables. Independent variables of $P < 0.05$ in the univariate analysis were selected in the subsequent multiple Logistic regression to identify independent risk factors. Predictive factors were chosen from independent risk factors. Finally, independent risk factors were put into new Logistic regression. We used Hosmer-Lemeshow Goodness of Fit Test and calibration plots to test classification accuracy. We evaluated the performance of our model and that of previously constructed models: $LSPS = [LSM \text{ (kPa)} \times SLD \text{ (cm)}]/PLT \times 10^9/L$ [7]; $AAR = AST/ALT$ [6]; $VRI = -4.364 + 0.538 \times SLD \text{ (cm)} - 0.049 \times PLT \times 10^9/L - 0.044 \times LSM \text{ (kPa)} + 0.001 \times (LSM \times PLT)$ [8]; and $APRI = [AST \text{ (U/L)}/AST \text{ (normal upper limit)}] \times 100/PLT \times 10^9/L$ [6].

Model performance

Receiver operating characteristic (ROC) curve was analyzed, area under the curve (AUC) and its corresponding 95%CI was measured to evaluate prediction effect[12]. We calculated the sensitivity (SEN), specificity (SPE), positive predictive value (PPV), negative predictive value (NPV) and Youden Index (YDI) to evaluate the accuracy and select cut-off value of prediction model.

External validation consisted of recalculating of AUC, Hosmer-Lemeshow Chi-square statistics and calibration plots to evaluate the discrimination ability and accuracy of prediction rule[13,14]. 56 subjects who met the inclusion criteria were taken in as the external validation group to prove the validity and generalization of the predictive rule. Decision curve analysis (DCA) was used to assess the population impact of using this prediction rule on clinical decision making[15,16].




Figure 1 Calibration plots of different group. A: Calibration scatter plot of modeling group; B: Calibration scatter plot of external validation group.




Figure 2 Receiver operating characteristic (ROC) of different group. A: Area under the curve (AUC) curve of the modeling group; B: AUC curve of the external validation group.

RESULTS

Subject characteristics

A total of 111 qualified subjects were enrolled in the modeling group, 86 (77.5%) were in EVs group. External validation group included 56 subjects. The characteristics of modeling group and the external validation group were shown in Tables 1 and 2.

Univariate analysis and multivariate analysis

Indices were compared between EVs group and non-EVs group (Table 3). Nine showed statistically significance in univariate analysis were entered in Logistic regression. In multivariable analysis, spleen volume change rate, liver volume change rate, CTSV, PVD and CTLV were independently associated ($P < 0.05$) with EVs (Table 4). The 5 variables were put in the predictive model.

Establishment of predictive model

The 5 selected independent factors were input to Logistic regression (Table 5). The prediction model was determined as: $\ln[P/(1-P)] = 12.93 - 0.01 \times \text{CTLV (cm}^3) + 0.02 \times \text{CTSV (cm}^3) + 0.01 \times (\text{CTLV-SLV}) (\text{cm}^3) - 1.93 \times [(\text{CTSV-SSV})/\text{SSV}] - 0.22 \times \text{PVD (mm)}$. The result of Hosmer-Lemeshow test was very good ($P = 0.90$), calibration plots were shown in Figure 1A. The AUC was 0.87 (95%CI: 0.80, 0.95), indicating the good discrimination ability (Figure 2A). The cut-off value was 0.85 on the ground of the maximum YDI (0.55); In light of the cut-off value, the SEN, SPE, PPV, NPV of the predictive model were 0.65, 0.90, 66.3%, 47%, respectively (Tables 6 and 7).

Comparison of prediction models' prediction effect

The AUC of the developed model was 0.87, compared with, the AUCs of the VRI (0.76), LSPS (0.76), AAR (0.63), and APRI (0.61) (Figure 2A), indicating the prediction effect of the model was better than other models. The developed model posited a 62.20% accuracy and a 66.3% positive predictive value (Tables 6 and 7), which were also better than other models.

Table 1 Comparison of general characteristics of the modeling group, *n*

Parameter	Patients with EVs, <i>n</i> = 86	Patients without EVs, <i>n</i> = 25	All patients, <i>n</i> = 111	<i>P</i> value
Age, yr	53.55 ± 11.58	51.32 ± 12.03	53.05 ± 11.12	0.28
Male (%)	47 (54.7)	17 (68.0)	64 (55.7)	0.47
Etiology, HBV/HCV	73/13	17/8	90/21	0.51
Child-Pugh class, A/B/C	45/34/7	21/4/0	66/38/7	< 0.01
Red Sign	36	0	36	< 0.01

P < 0.05 is considered statistical significance. EVs: Esophageal varices; HBV: Hepatitis B virus; HCV: Hepatitis C virus.

Table 2 Comparison of general characteristics of the external validation group, *n*

Parameter	Patients with EVs, <i>n</i> = 37	Patients without EVs, <i>n</i> = 19	All patients, <i>n</i> = 56	<i>P</i> value
Age, yr	51.46 ± 10.87	53.03 ± 11.41	54.68 ± 10.93	0.39
Male (%)	20 (54.1)	10 (52.6)	30 (53.6)	0.43
Etiology, HBV/HCV	27/10	15/4	42/14	0.56
Child-Pugh class, A/B/C	13/21/3	12/7/0	25/28/3	< 0.05
Red sign	14	0	14	< 0.01

P < 0.05 is considered statistical significance. EVs: Esophageal varices; HBV: Hepatitis B virus; HCV: Hepatitis C virus.

External validation of prediction model

AUC of the external validation group was 0.94 (95%CI: 0.88-0.99) (Figure 2B), indicating the model's good discrimination ability. The calibration in the external validation group was also good (*P* = 0.97), the calibration plots were shown in Figure 1B.

Clinical practicability of predictive model

From 35% to 100% highest risk threshold, the DCA curve (Figure 3A) of predictive model was higher than both two extreme lines, showing that from 35% to 100% risk threshold, patients may benefit and the prediction model had good clinical practicability. DCA curve of external validation group showed even better clinical practicability (Figure 3B).

DISCUSSION

The non-invasive prediction of EVs can be used as an initial screening tool for cirrhosis patients with EVs. We set up a clinical prediction model based on 5 readily clinical data, including spleen volume change rate, liver volume change rate, CTSV, PVD and CTLV, to help virus cirrhosis patients screen EVs and guide upper endoscopy. This is the first prediction model established based on PVD, liver and spleen volume, liver and spleen volume change rate. Consistent with our previous study, we found spleen volume change rate is associated with high-risk EVs[5]. Kim and Berzigotti found PLT, LSM and spleen longest diameter (SLD) were independent risk factors for predicting EVs[7,8]. Baveno VI Consensus recommended LSM < 20 kPa combined with platelet count > 150 × 10⁹/L can save 10% to 30% of upper endoscopy[17]. All the researchers put LSM in their model, which must be detected by FibroScan or FibroTouch. We approve of the above models. Actually, in China, there were no FibroScan or FibroTouch in many hospitals. In China, for patients with liver cirrhosis, CT was used as a routine examination to determine the degree of liver cirrhosis and exclude malignant lesions[18].

The AUC reflected the prediction effect of the model. Wang used APRI to predict EVs, and the AUC was 0.789, the sensitivity and specificity was 71% and 76%[6], respectively. Which was similar to the result of our study, and was lower than our prediction model. A variety of statistical analysis were used to evaluate the predictive model in three sides: Calibration, discrimination and clinical practicability. Based on the DCA curve of modeling group, patients with a risk from 35% to 100% may benefit from the model. Cut-off value was another critical index derived from ROC analysis, and each corresponding a SEN and SPE. The cut-off value were chosen according to the maximal YDI. In our study, we set the cut-off value at 0.85, if the cut-off value was changed, sensitivity may increase while specificity decreases.

Table 3 Univariate analysis of parameters of patients with esophageal varices and without esophageal varices

Parameter	Patients with EVs, n = 86	Patients without EVs, n = 25	P value
PVSA (mm ³)	211.96 ± 69.98	175.16 ± 77.43	0.04
PVD (mm)	13.76 ± 2.48	12.94 ± 2.73	< 0.05
SVD (mm)	9.54 ± 3.21	7.16 ± 3.36	< 0.01
CTLV (cm ³)	913.54 ± 312.89	1241.92 ± 34.83	< 0.01
CTSV (cm ³)	787.78 ± 399.46	439.23 ± 126.25	< 0.01
SSV (cm ³)	176.44 ± 31.21	195.71 ± 33.88	0.10
SLV (cm ³)	1049.40 ± 188.53	1136.97 ± 174.13	0.10
Rate of liver volume change	-0.12 ± 0.55	0.12 ± 0.48	< 0.01
Rate of spleen volume change	3.46 ± 2.49	1.38 ± 2.73	< 0.01
Liver volume change (cm ³)	135.85 ± 334.26	112.05 ± 280.68	0.01
Spleen volume change (cm ³)	243.52 ± 163.89	611.33 ± 293.17	< 0.01
ALT (IU/L)	32.08 ± 5.44	49.44 ± 7.63	0.16
AST (IU/L)	45.05 ± 7.98	65.28 ± 8.14	0.26
LSM (KPa)	21.68 ± 5.96	23.01 ± 5.24	0.29

$P < 0.05$ is considered statistical significance. EVs: Esophageal varices; PVSA: Portal vein surface area; PVD: Portal vein diameter; SVD: Splenic vein diameter; CTLV: Actual liver volume measured by computed tomography; CTSV: Actual spleen volume measured by computed tomography; SSV: Standard spleen volume measured by the formula; SLV: Standard liver volume measured by the formula; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; LSM: Liver stiff measurement.

Table 4 Multivariate analysis of parameters of patients with esophageal varices and without esophageal varices

Parameter	Patients with EVs (n = 86)	Patients without EVs (n = 25)	P value
PVSA (mm ³)	211.96 ± 69.98	175.16 ± 77.43	0.15
PVD (mm)	13.76 ± 2.48	12.94 ± 2.73	0.02
SVD (mm)	9.54 ± 3.86	7.16 ± 3.36	0.15
CTLV (cm ³)	913.54 ± 312.89	1241.92 ± 34.83	0.01
CTSV (cm ³)	787.78 ± 399.46	439.23 ± 126.25	0.02
Rate of liver volume change	-0.12 ± 0.55	0.12 ± 0.48	0.11
Rate of spleen volume change	3.46 ± 2.49	1.38 ± 2.73	0.04
Liver volume change (cm ³)	135.85 ± 334.26	112.05 ± 280.68	0.03
Spleen volume change (cm ³)	243.52 ± 163.89	611.33 ± 293.17	> 0.05

$P < 0.05$ is considered statistical significance. EVs: Esophageal varices; PVSA: Portal vein surface area; PVD: Portal vein diameter; SVD: Splenic vein diameter; CTLV: Actual liver volume measured by computed tomography; CTSV: Actual spleen volume measured by computed tomography.

Our research has several highlights. First of all, it is applicable to hospitals without FibroScan or FibroTouch in China. The indexes included in the model can be obtained by CT and standard liver/spleen volume formula. Secondly, all the patients enrolled in the study were virus cirrhosis, with good uniformity, the results were true and reliable. Thirdly, similar to Kim's study[7], our model aims at the prediction of EVs, and it provides an ideal quantitative tool for clinical early warning and diagnosis of EVs.

There were some limitations in our research: First, it is a retrospective study rather than cohort study and samples were collected in only one hospital, it may cause admission and selection bias; Second, this study was limited by the low sample size, and depended on CT, which has associated radiation risk. Third, due to the differences in spleen and liver volume changes between viral cirrhosis patients and other forms of cirrhosis the promotion and application of the developed model may be limited. Finally,

Table 5 Parameters used to establish the non-invasive prediction model

Parameter	B	S.E	Wals	df	Sig.	Exp (B)	95%CI of EXP (B)
PVD (mm)	-0.216	0.184	1.384	1	0.239	0.806	0.562-1.155
CTLV (cm ³)	-0.013	0.004	9.465	1	0.002	0.987	0.979-0.995
CTSV (cm ³)	0.016	0.006	7.047	1	0.008	1.016	1.004-1.028
Rate of spleen volume change	-1.929	0.895	4.646	1	0.031	0.145	0.025-0.839
liver volume change (cm ³)	0.009	0.004	5.112	1	0.024	1.009	1.001-1.016
Constant	12.925	4.414	8.573	1	0.003	410393	

PVD: Portal vein diameter; CTLV: Actual liver volume measured by computed tomography; CTSV: Actual spleen volume measured by computed tomography; df: Degree of freedom; CI: Confidence interval.

Table 6 Comparison of various parameters of each model

	AUC	Standard error	Sig.	95%CI of EXP(B)				
				Lower limit	Upper limit	Sensitivity	Specificity	Youden index
New model	0.873	0.040	0.000	0.795	0.951	0.653	0.897	0.55
LSPS	0.757	0.053	0.000	0.652	0.861	0.667	0.759	0.426
VRI	0.757	0.053	0.000	0.653	0.862	0.647	0.828	0.475
APRI	0.607	0.074	0.120	0.462	0.753	0.696	0.552	0.248
AAR	0.627	0.073	0.067	0.483	0.770	0.588	0.793	0.381

CI: Confidence interval; LSPS: Liver stiffness-spleen diameter to platelet ratio score; VRI: Variceal risk index; APRI: Aspartate transaminase to platelet ratio index; AAR: Aspartate transaminase/ Alanine aminotransferase ratio.

Table 7 Comparison of accuracy of each model in predicting esophageal varices of patients in the modeling group

	Accuracy, %	Positive predictive value, %	Negative predictive value, %	Cutoff value
New model	62.2	66.3	47.0	0.849
LSPS	52.2	52.2	36.0	3.77
VRI	47.8	52.3	38.5	0.029
APRI	53.2	62.8	20.0	1.17
AAR	45.0	41.9	44.0	1.43


LSPS: Liver stiffness-spleen diameter to platelet ratio score; VRI: Variceal risk index; APRI: Aspartate transaminase to platelet ratio index; AAR: Aspartate transaminase/ Alanine aminotransferase ratio.

with the discover of potential and unknown risk factors of EVs, the clinical efficacy of the prediction model may be reduced. In the future, we need to add new and potential factors to optimize and verify the predictive model.

Despite the limitations, the prediction model can help accurately and effectively predict EVs in patients with virus cirrhosis, which provides an ideal quantitative tool for clinical early warning and diagnosis of EVs.

CONCLUSION

In conclusion, based on the standard liver and spleen volume formula, a non-invasive predictive model with good discriminating ability, calibration ability and the clinical practicability was established. The model is a useful tool for early diagnosis of EVs in patients with viral cirrhosis.



DOI: 10.12998/wjcc.v10.i32.11743 Copyright ©The Author(s) 2022.

Figure 3 Decision curve analysis curve of prediction model. The black line showed that in an extreme case, none of the crowd had EVs, sNT = 0; The grey line showed that in another extreme case, all of the crowd had EVs, the slope of sNT was negative; A: Decision curve analysis (DCA) curve of modeling group; B: DCA curve of external validation group.

ARTICLE HIGHLIGHTS

Research background

Although there are reports of models predicting esophageal varices; however, there were no models based on the standard liver and spleen volume calculation formula.

Research motivation

It is highly important to identify virus patients with esophageal varices (EVs) and guide them for gastroscopy, and a non-invasive predictive model can be used to identify EVs.

Research objectives

A non-invasive predictive model for EVs based on liver and spleen volume in viral cirrhosis patients.

Research methods

A cross-sectional study based on viral cirrhosis crowd were conducted in the Second Affiliated Hospital of Xi'an Jiaotong University. By collecting the participants' basic information and clinical data of the, we derived the independent risk factors and established the prediction model of EVs. We compared the established model with others. Area under the receiver operating characteristic curve, calibration plot and decision curve analysis were used to test the discriminating ability, calibration ability and clinical practicability in both internal and external validation group.

Research results

The portal vein diameter, the liver and spleen volume, and volume change rate were successfully used to establish the predictive model, which showed better predictive value than other models. The model indicating good discriminating ability, calibration ability and clinical practicability in both modelling and external validation group.

Research conclusions

The developed model is a credible predictor of EVs with high specificity, calibrability and clinical efficacy.

Research perspectives

Further studies to confirm this model's potential using larger sample sizes are recommended. Besides, there is need to develop predictive models with high diagnostic accuracy, while considering the limitations herein.

FOOTNOTES

Author contributions: Yang LB, Zhao G and Dong L designed the research study; Tan-tai XX and Xiao CL performed the research; Jia Y and Chang DY contributed new reagents and analytic tools; Qing SW and Li H analyzed the data and wrote the manuscript; All authors have read and approve the final manuscript.

Supported by Key Research and Development Plan of Shaanxi Province, No. 2020SF-222.

Institutional review board statement: The study was approved by the Ethics Committee of Xi'an Jiaotong University, Shaanxi, China (NO. 2017-445).

Informed consent statement: Informed consent was waived by the Ethics Committee of Xi'an Jiaotong University as patients were identified retrospectively, according to institutional review board exempt protocols.

Conflict-of-interest statement: There are no conflicts of interest to declare.

Data sharing statement: Technical appendix, statistical code, and dataset available from the corresponding author at hongli119@hotmail.com.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <https://creativecommons.org/licenses/by-nc/4.0/>

Country/Territory of origin: China

ORCID number: Long-Bao Yang 0000-0001-7731-0910; Gang Zhao 0000-0003-1118-619X; Xin-Xing Tantai 0000-0002-4105-6890; Cai-Lan Xiao 0000-0001-8476-5008; Si-Wen Qin 0000-0003-0312-0369; Lei Dong 0000-0002-4768-7896; Dan-Yan Chang 0000-0003-2560-9704; Yuan Jia 0000-0002-3290-8481; Hong Li 0000-0002-5284-7882.

S-Editor: Liu JH

L-Editor: A

P-Editor: Liu JH

REFERENCES

- Maydeo A, Patil G. How to Approach a Patient with Gastric Varices. *Gastroenterology* 2022; **162**: 689-695 [PMID: 34979100 DOI: 10.1053/j.gastro.2021.12.277]
- Stanley AJ, Laine L. Management of acute upper gastrointestinal bleeding. *BMJ* 2019; **364**: 1536 [PMID: 30910853 DOI: 10.1136/bmj.1536]
- Masuda Y, Yoshizawa K, Ohno Y, Mita A, Shimizu A, Soejima Y. Small-for-size syndrome in liver transplantation: Definition, pathophysiology and management. *Hepatobiliary Pancreat Dis Int* 2020; **19**: 334-341 [PMID: 32646775 DOI: 10.1016/j.hbpd.2020.06.015]
- Ikegami T, Balci D, Jung DH, Kim JM, Quintini C. Living donor liver transplantation in small-for-size setting. *Int J Surg* 2020; **82S**: 134-137 [PMID: 32738547 DOI: 10.1016/j.ijssu.2020.07.003]
- Yang LB, Xu JY, Tantai XX, Li H, Xiao CL, Yang CF, Zhang H, Dong L, Zhao G. Non-invasive prediction model for high-risk esophageal varices in the Chinese population. *World J Gastroenterol* 2020; **26**: 2839-2851 [PMID: 32550759 DOI: 10.3748/wjg.v26.i21.2839]
- Wang JH, Chuah SK, Lu SN, Hung CH, Chen CH, Kee KM, Chang KC, Tai WC, Hu TH. Transient elastography and simple blood markers in the diagnosis of esophageal varices for compensated patients with hepatitis B virus-related cirrhosis. *J Gastroenterol Hepatol* 2012; **27**: 1213-1218 [PMID: 22432969 DOI: 10.1111/j.1440-1746.2012.07132.x]
- Kim BK, Han KH, Park JY, Ahn SH, Kim JK, Paik YH, Lee KS, Chon CY, Kim DY. A liver stiffness measurement-based, noninvasive prediction model for high-risk esophageal varices in B-viral liver cirrhosis. *Am J Gastroenterol* 2010; **105**: 1382-1390 [PMID: 20087336 DOI: 10.1038/ajg.2009.750]
- Berzigotti A, Seijo S, Arena U, Abruñales JG, Vizzutti F, García-Pagán JC, Pinzani M, Bosch J. Elastography, spleen size, and platelet count identify portal hypertension in patients with compensated cirrhosis. *Gastroenterology* 2013; **144**: 102-111.e1 [PMID: 23058320 DOI: 10.1053/j.gastro.2012.10.001]
- de Franchis R; Baveno VI Faculty. Expanding consensus in portal hypertension: Report of the Baveno VI Consensus

- Workshop: Stratifying risk and individualizing care for portal hypertension. *J Hepatol* 2015; **63**: 743-752 [PMID: [26047908](#) DOI: [10.1016/j.jhep.2015.05.022](#)]
- 10 **Wang R**, Ren W, Zhao S, Niu X, Tan P, Du H, Nan Y. [Clinical study on FibroTouch and multi-parameter model for diagnosis of hepatic fibrosis in patients with chronic liver disease]. *Zhonghua Gan Zang Bing Za Zhi* 2015; **23**: 265-269 [PMID: [26133817](#) DOI: [10.3760/cma.j.issn.1007-3418.2015.04.007](#)]
- 11 **Feld J**, Janssen HL, Abbas Z, Elewaut A, Ferenci P, Isakov V, Khan AG, Lim SG, Locarnini SA, Ono SK, Sollano J, Spearman CW, Yeh CT, Yuen MF, LeMair A; Review Team:. World Gastroenterology Organisation Global Guideline Hepatitis B: September 2015. *J Clin Gastroenterol* 2016; **50**: 691-703 [PMID: [27623512](#) DOI: [10.1097/MCG.0000000000000647](#)]
- 12 **Hanley JA**, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. *Radiology* 1982; **143**: 29-36 [PMID: [7063747](#) DOI: [10.1148/radiology.143.1.7063747](#)]
- 13 **Cai QC**, Yu ED, Xiao Y, Bai WY, Chen X, He LP, Yang YX, Zhou PH, Jiang XL, Xu HM, Fan H, Ge ZZ, Lv NH, Huang ZG, Li YM, Ma SR, Chen J, Li YQ, Xu JM, Xiang P, Yang L, Lin FL, Li ZS. Derivation and validation of a prediction rule for estimating advanced colorectal neoplasm risk in average-risk Chinese. *Am J Epidemiol* 2012; **175**: 584-593 [PMID: [22328705](#) DOI: [10.1093/aje/kwr337](#)]
- 14 **Schroy PC 3rd**, Wong JB, O'Brien MJ, Chen CA, Griffith JL. A Risk Prediction Index for Advanced Colorectal Neoplasia at Screening Colonoscopy. *Am J Gastroenterol* 2015; **110**: 1062-1071 [PMID: [26010311](#) DOI: [10.1038/ajg.2015.146](#)]
- 15 **Vickers AJ**, Cronin AM, Elkin EB, Gonen M. Extensions to decision curve analysis, a novel method for evaluating diagnostic tests, prediction models and molecular markers. *BMC Med Inform Decis Mak* 2008; **8**: 53 [PMID: [19036144](#) DOI: [10.1186/1472-6947-8-53](#)]
- 16 **Kerr KF**, Brown MD, Zhu K, Janes H. Assessing the Clinical Impact of Risk Prediction Models With Decision Curves: Guidance for Correct Interpretation and Appropriate Use. *J Clin Oncol* 2016; **34**: 2534-2540 [PMID: [27247223](#) DOI: [10.1200/JCO.2015.65.5654](#)]
- 17 **Chinese Society of Hepatology**; Chinese Medical Association. [Chinese guidelines on the management of liver cirrhosis]. *Zhonghua Gan Zang Bing Za Zhi* 2019; **27**: 846-865 [PMID: [31941240](#) DOI: [10.3760/cma.j.issn.1007-3418.2019.11.008](#)]
- 18 **Liang Z**, Liu Y, Nie Y. Efficacy Analysis of Double-Low Dynamic Contrast-Enhanced CT and Hepatic Extracellular Volume Fraction in the Diagnosis of Liver Fibrosis. *Contrast Media Mol Imaging* 2022; 2022: 8089914 [PMID: [36072627](#) DOI: [10.1155/2022/8089914](#)]



Published by **Baishideng Publishing Group Inc**
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Telephone: +1-925-3991568

E-mail: bpgoffice@wjgnet.com

Help Desk: <https://www.f6publishing.com/helpdesk>

<https://www.wjgnet.com>

